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Abstract
Background: One of the problems arising from available preparations for dry eye syndrome is the
limited residence time of products on the ocular surface. In this paper, we look at an innovative
new treatment for dry eye, tamarind seed polysaccharide (TSP). TSP possesses mucomimetic,
mucoadhesive and pseudoplastic properties. The 'mucin-like' molecular structure of TSP is similar
to corneal and conjunctival mucin 1 (MUC1), a transmembrane glycoprotein thought to play an
essential role in protecting and wetting the corneal surface and may explain its increased retention
on the eye surface.
Methods: The activity of TSP and hyaluronic acid (HA) in the treatment of dry eye syndrome was
compared in an open-label, randomised, single-centre clinical study. Thirty patients were
randomised to receive three or more applications per day of either TSP 0.5%, TSP 1% or HA 0.2%
(Hyalistil™) over a period of 90 days. The primary objective of tolerability was assessed by visual
analogue scale (VAS), scoring of specific symptoms and the incidence of adverse events. Secondary
objectives included improvement in stability of the precorneal tear film, subjective symptoms and
corneal and conjunctival staining.
Results:  TSP 0.5% and 1% were comparable to HA 0.2% with regard to both primary and
secondary objective parameters.
TSP 1% showed benefits over HA 0.2% for the subjective symptoms; trouble blinking, ocular
burning and foreign body sensation.
Conclusion: This study suggests that TSP 0.5% and 1% offer at least equivalent relief to HA 0.2%
for dry eye syndrome. All treatments demonstrated optimal tolerability and are suitable for
frequent use in the therapy of dry eye.
TSP 1% produced promising results in terms of improvements in certain patient symptoms and 
suggests benefits of the TSP formulation. This study paves the way for a larger study to further 
establish the performance and safety of TSP compared with HA and highlights the need to expand 
this therapeutic agent to a wider dry eye population.
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Background
Dry eye symptoms are most commonly treated with eye
drops, the major component of which is usually a viscos-
ity-enhancing polymer. Such formulations are designed to
act on the mucus and aqueous layers of the tear film,
replacing lost moisture and stabilising the tear film. An
issue with currently available preparations is their limited
residence time on the ocular surface. In this paper, we
look at an innovative new treatment for dry eye, tamarind
seed polysaccharide. It is thought that the increased reten-
tion time observed with TSP on the ocular surface can be
explained by similarity of the structure of TSP to trans-
membrane mucins, such as MUC1.
Goblet cells and lacrimal glands synthesise a spectrum of
mucins that are involved in the pathophysiological events
that occur at the ocular surface [1]. In the tear film, a
mucus gel anchors itself and, therefore, the tear film, to
the ocular surface via physicochemical interactions [2,3].
The integrity of this mucus gel, together with all the layers
of the tear film, is responsible for the maintenance of nor-
mal vision and ocular comfort.
Effective distribution of the tear film across the ocular sur-
face occurs via blinking. The healthy corneal epithelium is
wettable by itself because of its ability to produce and
maintain the transmembrane glycoprotein layer (MUC1).
MUC1 is a membrane spanning mucin, expressed by the
stratified epithelium of the conjunctiva and is believed to
facilitate the spread of gel-forming mucin. Mucins possess
surface activity and, in physiological concentrations, the
presence of the mucin layer in the tear film converts the
corneal epithelium from a hydrophobic to a hydrophilic
surface so that the tear film can be spread over the cornea.
If the production of mucus is reduced (for example, due
to goblet cell damage, age or hormonal status), [1] mucus
distribution over the preocular surface is impaired, lead-
ing to poor contact of the tear film with the eye surface
and a loss of film stability [4].
Figure 1 shows the location and extent of epithelial
mucins on the ocular surface in a healthy eye compared
with a severe dry eye. The last ten years have seen remark-
able progress in understanding the structure and character
of mucins [5]. Recent application of molecular techniques
has demonstrated 14 human mucin genes, e.g. MUC1 and
MUC5. Of these, the mucins are now classified into gel-
forming or secreting, (e.g., MUC5), soluble, (e.g., MUC7),
and transmembrane, (e.g., MUC1). Gel-forming mucins
are responsible for the rheological properties of mucus,
whereas transmembrane mucins form a dense barrier in
the glycocalyx at the epithelial tear film interface. In
healthy tear film, transmembrane-spanning mucins of the
glycocalyx provide a negatively charged, hydrated, epithe-
lial cell surface which supports and facilitates spreading of
the hydrated tear film – a mucous gel – with its associated
defence molecules. With loss of tear volume, lipid layer,
glycocalyx mucins and/or gel forming mucins, dry spots
develop on the eye, leading to keratinisation and loss of
mucin gene expression by the epithelial cells. It is hypoth-
esised that loss or alteration of the membrane-spanning
mucins alone or in combination with MUC5AC-secreted
mucin induces dry spot formation [6].
On the ocular surface, epithelial mucins serve as:
￿ Pre-ocular tear film stabilisers to prevent dehydration of
the underlying epithelium
￿ A barrier against pathogen penetration
￿ Wetting and lubricant agents of the cornea and conjunc-
tiva during blinking
￿ Promoters of adhesion between tear film layers through
hydrogen bonding
Table 1 shows the characteristics of mucin-deficient dry
eye.
TSP formulation
TSP is a new formulation derived from the tamarind seed.
The main component of tamarind seed has been identi-
fied as a non-ionic, neutral, branched polysaccharide con-
sisting of a cellulose-like backbone that carries xylose and
galactoxylose substituents, [7] chemical residues similar
to those of MUC1. The configuration of TSP gives the
product a 'mucin-like' molecular structure, [8] with partic-
ular similarity to MUC1 (Figure 2), thus conferring opti-
mal mucoadhesive properties.
Research has also shown that, at the concentrations
present in the ophthalmic formulations studied, TSP has
an important characteristic that makes it similar to natural
tears, i.e. its ability to crystallise in a fern-like shape [9].
It has been suggested that the similarity of the structure of
TSP to endogenous mucin may allow a formulation con-
taining this polymer to adhere readily to the ocular surface
for prolonged periods and provide sustained relief from
the symptoms of dry eye [10]. Indeed, studies undertaken
to date suggest that TSP may have some benefits over HA
relating to ocular retention time, wound healing proper-
ties and relief of dry eye symptoms [8,11].
Overall, TSP has several physicochemical properties that
make it suitable for the management of dry eye syndrome
(Table 2) and which potentially have distinct advantages
over currently available preparations.BMC Ophthalmology 2007, 7:5 http://www.biomedcentral.com/1471-2415/7/5
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A study was performed to test this promising new agent
against HA in the treatment of dry eye syndrome.
Methods
This open-label, randomised, comparative clinical study
compared the activity of TSP 0.5% and 1% vs. HA 0.2%
(Hyalistil™). A total of thirty patients with dry eye syn-
drome were recruited (TSP 0.5% n = 11; TSP 1% n = 10;
HA 0.2% n = 9).
Patient demographics
Baseline characteristics of enrolled patients are summa-
rised in Table 3.
Subjects were given three or more applications per day of
the randomised study treatment over a period of 90 days.
Patients were included if they were over 18 years of age,
had a tear break-up time (BUT) < 10 seconds, dry eye
symptoms (2 >6 cm on VAS), a Schirmer I test = 5 mm/5
The location and extent of epithelial mucins on the ocular surface Figure 1
The location and extent of epithelial mucins on the ocular surface.
Table 1: Characteristics of mucin-deficient dry eye
• Instability of tear film
• Presence of non-wetted areas on the corneal and conjunctival surfaces
• Decreased mucin production
• Altered mucin distribution
• Keratisation of the cornea and conjunctiva
• Loss of conjunctival goblet cellsBMC Ophthalmology 2007, 7:5 http://www.biomedcentral.com/1471-2415/7/5
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min and positive testing = 2 in at least one area of ocular
surface. Patients were excluded if they were pregnant or
breastfeeding, had eye surgery in the previous three
months, were on other ocular therapies or had other eye
pathologies.
The primary objective of this study was to evaluate the tol-
erability of topical ocular administration of TSP in
patients presenting with dry eye. This was assessed by a
specific VAS tolerability questionnaire and by data relat-
ing to adverse events. Secondary objectives were to evalu-
ate improvement in the stability of the precorneal tear
film with the study treatments and to assess any changes
in subjective symptoms and ocular surface staining.
Table 4 shows the assessment of tolerability and perform-
ance.
Tolerability data were recorded throughout the study by
means of a VAS questionnaire listed per single visit. The
sum total of VAS scores for all the questions, recorded
after 90 days of treatment for the three groups, was evalu-
ated by ANOVA, followed by multiple comparisons by
Tukey's test. Differences relating to the trend of this varia-
ble over the 90-day study period were evaluated by means
of ANOVA for repeated measurements. Any adverse
events received in the study were to be described in full
detail and differences amongst treatment groups evalu-
ated accordingly (chi-square test). All treated patients
were recorded in the tolerability evaluation.
Subjects in the study were assessed on days 0 (baseline),
14, 30, 60 and 90. Data have been collected from both
eyes of each patients in all groups. All data have been used
for statistical analysis.
At baseline, the IOP ranged from 12–19 mmHg with no
difference between treatment groups and the BUT mean
values were around 5 seconds for all treatments, ranging
from 3–8 seconds.
This trial was carried out in accordance with the Helsinki
declaration and patients' informed consent was obtained
prior to commencing the study. The Study was approved
by the ethics committee of S. Martino Hospital in Genoa,
Italy [12].
Results
In terms of the primary objective of evaluating tolerabil-
ity, a questionnaire was used to detect the onset of blurred
vision, ocular redness, ocular burning and ocular itching
immediately after instillation of the preparations. For the
entire duration of the study, there was no reported onset
of any of the tolerability parameters assessed (Table 4).
Furthermore, there were no adverse events reported
throughout the study in any of the treatment groups.
Tables 5, 6, 7, 8, 9 present the results of the secondary
objectives. Subjective symptoms were improved in all
treatment groups (Table 5). However, there were some
significant differences observed between the groups. TSP
1% showed benefits over HA in certain of the subjective
VAS scores, with significant differences between treat-
ments for the factors shown in Table 6. There were no
inter-treatment differences (i.e. no superiority vs. compa-
rator) for clinical measurements.
Furthermore, it was observed that TSP 0.5% and 1% dem-
onstrated efficacy with significant inter-visit differences (p
< 0.05) for the following:
￿ Subjective symptom improvements: Blinking trouble,
ocular burning, sensation of foreign body, wish to keep
eyes shut, photophobia, ocular pain
Configuration of TSP Figure 2
Configuration of TSP.
Table 2: Physicochemical properties of TSP
• Chemical structure similar to membrane-bound ocular mucins
• Non-Newtonian rheologic behaviour
• Ferning pattern similar to natural tear film
• Mucomimetic, mucoadhesive and pseudoplastic propertiesBMC Ophthalmology 2007, 7:5 http://www.biomedcentral.com/1471-2415/7/5
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￿ Performance improvements: Tear film break up time,
corneal and conjunctival damage
Intraocular pressure
Concerning IOP, all treatments showed relatively stable
values during the study period; mean values remained
around 14–15 mmHg, ranging from 12–19 mmHg.
Changes between baseline and day-60 visit (no assess-
ment at final visit was foreseen) were negligible for all
treatments and in both eyes.
Average number of daily instillations
The average number of daily instillations was found to be
similar in three treatment groups throughout the study,
ranging between 3 and 4 instillations with no statistically
significant difference.
Tear film break up time (BUT)
In terms of tear film break up time, mean values are
shown in Tables 7 and 8. Analysis of the time-course of
values showed a significant increase in values between
baseline and final visit (ANOVA between visits p < 0.05).
There were no observed differences between treatments.
Corneal and conjunctival staining
Importantly, for both corneal and conjunctival damage in
both eyes, there was a statistically significant decrease in
total staining score between baseline and final visit in all
three treatment groups, with no statistically significant
differences observed between groups (Figure 3).
Discussion
TSP is a neutral polymer that, unlike the majority of vis-
cosity enhancing polymers, has a branched-chain struc-
ture similar to that of corneal and conjunctival mucus
transmembrane proteins. It has mucomimetic, mucoad-
hesive and pseudoplastic properties that may account for
the benefits observed in improving dry eye signs and
symptoms.
In this study comparing TSP with HA, all preparations
demonstrated optimal tolerability, with no reported onset
of blurred vision, ocular redness, ocular burning or ocular
itching. This confirms their suitability, even for frequent
use, as tear substitutes in the treatment of dry eye. Clinical
performance was also demonstrated with all treatments.
Table 4: Assessment of tolerability and performance
Tolerability – primary objectives
a. VAS tolerability questionnaire to evaluate:
• Blurred vision
• Ocular redness
• Ocular burning
• Ocular itching
b. Adverse events
Performance – secondary objectives
• Clinical/symptomatologic evaluation (symptoms were evaluated using a VAS questionnaire recording: discomfort when blinking, burning, 
foreign body sensation, sensation of ocular fatigue/heaviness, sensation of tearing, desire to keep eyes closed, sensation of photophobia, 
sensation of blurred vision and sensation of pain)
• Corneal and conjunctival staining
• Intraocular pressure (IOP)
• Tear film break-up time (BUT)
• Number of daily instillations
Table 3: Demographic characteristics and medical history data*
TSP 0.5% (n = 11) TSP 1% (n = 10) HA 0.2% (n = 9)
Gender
Female 6 (54.5%) 6 (60.0%) 8 (88.8%)
Male 5 (45.4%) 4 (40.0%) 1 (11.1%)
Age (years)
Mean (SD) 59.01 (13.83) 62.33 (13.06) 59.45 (10.60)
Min – Max 41.28 – 82.36 47.16 – 90.62 45.11 – 70.34
Sjogren's Syndrome 3 (27.3%) 4 (40.0%) 3 (33.3%)
* No statistically significant differences were observed between groupsBMC Ophthalmology 2007, 7:5 http://www.biomedcentral.com/1471-2415/7/5
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All study preparations produced an improvement in
many of the subjective symptoms assessed. The significant
differences between products in some subjective symp-
tom scores are interesting and warrant further investiga-
tion in a larger study population. Of particular note is the
significant improvement in scores observed with TSP 1%
between baseline and final visits for symptoms relating to
trouble blinking, ocular burning and sensation of foreign
body. These results suggest that TSP 1% may improve
patient quality of life (Table 6).
The results with BUT are particularly interesting. Under
normal conditions, blinking generally occurs at an aver-
age of 10–15 movements per minute (one blink every 4–
6 seconds). Reports of spontaneous eye blink rate vary
widely however and in some situations may be less than
seven blinks per minute (one blink every 8.5 seconds). It
is desirable for the tear film to remain intact between
blinks so that the eye surface is 'protected' and a BUT of 8
seconds is often taken as a target. This may not only pro-
duce a benefit in terms of symptoms but also interrupts
the onset of the cycle of tear instability/epithelial injury/
tear instability that maintains and worsens dry eye syn-
drome [13]. Indeed, reports even cite that a BUT >10 sec-
onds is required to protect ocular surface [14].
Vital dyes such as fluorescein and rose bengal are com-
monly used in ophthalmology to assess the extent and
severity of damage to the ocular surface epithelium [15].
Importantly, statistically significant improvements
between baseline and final visits were observed with
respect to corneal and conjunctival staining, suggesting an
improvement in the health of the ocular surface epithe-
lium.
Lastly, the inclusion criteria used have allowed for recruit-
ment of patients with Sjögren's syndrome. An analysis of
the sub-set of patients with this condition was performed
for this trial and, although patient numbers were insuffi-
cient to reach significance, trends in these data suggest an
improvement in BUT and symptom scoring with TSP in
this challenging patient population.
TSP clinical studies to date have produced interesting
results. A randomised, blinded four-way crossover scinti-
graphic investigation of precorneal residence time of 3
TSP concentrations (0.5%, 1.0% and 2.0%) and HA 0.4%
was conducted in 12 patients with mild to moderate dry
eye syndrome, aged between 35–75 years [11]. Whilst TSP
0.5% was found to have a comparable profile to HA 0.4%,
dynamic corneal residence-time curves showed that TSP
1% and 2% formulations demonstrated greater retention
than HA 0.4%. The authors concluded that this pattern of
retention strongly suggests a tear-structuring effect of TSP
[11].
There are some limitations and additional aspects to this
study worth considering. The fact that varying TSP con-
Table 6: Dry eye symptoms: significant inter-treatment differences
Trouble blinking TSP 1% vs. HA 0.2%; p < 0.05
Ocular burning TSP 1% vs. HA 0.2%; p < 0.05
TSP 1% vs. TSP 0.5%; p < 0.05
Sensation of foreign body TSP 1% vs. HA 0.2%; p < 0.05
Table 5: Results
Blinking 
trouble*
Ocular 
burning**
Sensation of 
foreign 
body***
Sensation of 
lachrymation°
Ocular fatigue/
load sensation°
Wish to keep 
eyes shut°
Photophobia°
0.5% TSP (n = 11)
Baseline Mean (SD) 81.55 (27.62) 86.09 (14.49) 89.64 (9.06) 8.64 (28.64) 25.45 (43.69) 31.45 (45.23) 8.82 (29.25)
Visit 5 (day 90) Mean (SD) 38.00 (22.46) 43.45 (13.92) 36.82 (15.42) 4.55 (15.08) 15.73 (27.38) 16.27 (24.69) 4.73 (15.68)
1% TSP (n = 10)
Baseline Mean (SD) 81.20 (31.93) 93.00 (8.62) 90.50 (9.64) 9.50 (30.04) 9.70 (30.67) 40.60 (45.74) 14.70 (32.76)
Visit 5 (day 90) Mean (SD) 16.50 (16.21) 22.30 (13.70) 16.60 (16.79) 4.40 (13.91) 3.20 (10.12) 5.90 (10.35) 1.20 (3.79)
0.2% HA (n = 9)
Baseline Mean (SD) 63.22 (40.39) 78.78 (30.76) 72.00 (31.08) 0.00 (0.00) 10.78 (32.33) 59.67 (45.17) 25.00 (38.98)
Visit 5 (day 90) Mean (SD) 40.67 (28.27) 50.44 (22.11) 42.78 (29.47) 0.00 (0.00) 9.33 (21.29) 28.67 (35.12) 12.44 (24.00)
* TSP 1% vs. HA 0.2%; p < 0.05
** TSP 1% vs. HA 0.2%; p < 0.05, TSP 1% vs. TSP 0.5%; p < 0.05
*** TSP 1% vs. HA 0.2%; p < 0.05
° p = NSBMC Ophthalmology 2007, 7:5 http://www.biomedcentral.com/1471-2415/7/5
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centrations and HA are distinguishable by appearance,
viscosity and delivery device necessitates the use of an
open label trial. In addition, as the trial was not placebo-
controlled, patients were aware of receiving an interven-
tion and, therefore, it is possible that this may have
impacted on patients' subjective scoring of dry eye symp-
tomatology.
Conclusion
This study has demonstrated that TSP 0.5% and 1% are
comparable to HA 0.2% according to the variables meas-
ured in the study. Due to the absence of both onset and
incidence of adverse events reported throughout the
study, it is concluded that all treatments demonstrated
optimal tolerability and are suitable for frequent use in
the therapy of dry eye. Statistically significant improve-
ments between baseline and final visits were observed
with respect to tear film break up time and corneal and
conjunctival damage.
However, the results obtained with the subjective VAS
symptom scores suggest benefits of the TSP 1% formula-
tion (Table 9). It is possible that the effects seen with TSP
could translate into significant differences in objective
clinical measurements in a larger study population. Fur-
thermore, data analyses indicate that TSP might, over a
period of time, produce improvement in tear film stabil-
ity, thereby improving eye conditions and overall patient
quality of life.
Abbreviations
HA Hyaluronic acid
TSP Tamarind seed polysaccharide
VAS Visual Analogue Scale
Graph showing corneal staining total score over time Figure 3
Graph showing corneal staining total score over time.
Table 8: BUT – changes from baseline to final visit (90 days)
Treatment n Mean
0.5% TSP 11 4.45*
1% TSP 10 4.40*
0.2% HA 9 3.22*
* ANOVA between treatments; p < 0.05
Table 7: Tear film break up time (BUT)
TSP 0.5% (n = 11) TSP 1% (n = 10) HA 0.2%(n = 9)
Baseline Mean (SD) 5.18 (1.33) 5.00 (1.33) 5.22 (1.79)
Day 15 Mean (SD) 6.64 (2.11) 6.20 (1.48) 6.00 (2.18)
Day 30 Mean (SD) 7.64 (1.96) 7.20 (1.55) 6.78 (2.28)
Day 60 Mean (SD) 8.45 (2.30) 8.30 (1.42) 8.00 (2.65)
Day 90 Mean (SD) 9.64 (2.29) 9.40 (1.35) 8.44 (2.51)
Table 9: Summary of trial results of TSP vs. HA 0.2%
• TSP is effective at concentrations of 0.5% and 1% in treating dry eye syndrome, demonstrated by its effect on tear film break up time, corneal and 
conjunctival damage and its ability to provide symptom relief over a 90 day period
• TSP 0.5% and 1% show equivalent performance to HA 0.2% with regard to improving tear film break up time
• TSP 1% produced a significantly greater effect compared with HA 0.2% in some patient-scored symptomsPublish with BioMed Central    and   every 
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BUT Break up time
MUC1 conjunctival mucin 1
IOP Intraocular pressure
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